Protagonist Therapeutics Q2 net loss beats expectations
Overview
Protagonist Q2 net loss $34.8 mln, beating analyst expectations, per LSEG data
License and collaboration revenue rose to $5.5 mln in Q2
Income from operations missed expectations due to higher operating expenses
Outlook
Protagonist expects rusfertide NDA filing in Q4 2025
Company anticipates cash runway through end of 2028
Result Drivers
INCREASED R&D EXPENSES - Rise in R&D costs driven by new product candidates PN-881 and PN-477
LICENSE REVENUE GROWTH - License and collaboration revenue increased due to Takeda collaboration milestone
HIGHER G&A COSTS - Increase in G&A expenses attributed to stock-based compensation and personnel costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 License and Collaboration Revenue | $5.55 mln | ||
Q2 EPS | -$0.55 | ||
Q2 Net Income | Beat | -$34.77 mln | -$35.10 mln (9 Analysts) |
Q2 Income from Operations | Miss | -$42.04 mln | -$40.10 mln (10 Analysts) |
Q2 Basic EPS | -$0.55 | ||
Q2 Operating Expenses | $47.59 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00, about 23% above its August 5 closing price of $53.90
Press Release:
